Journal Article
. 2013 Jan;3(1).
doi: 10.1158/2159-8290.CD-12-0462.

The genomic landscape of breast cancer as a therapeutic roadmap

Matthew J Ellis 1 Charles M Perou  
Affiliations
  • PMID: 23319768
  •     44 References
  •     81 citations

Abstract

The application of high-throughput techniques to profile DNA, RNA, and protein in breast cancer samples from hundreds of patients has profoundly increased our knowledge of the disease. The etiologic events that drive breast cancer are finally coming into focus and should be used to set priorities for clinical trials. In this Prospective, we summarize some of the headline conclusions from 6 recent breast cancer "omics profiling" articles in Nature, with an emphasis on the implications for systemic therapy.

MDM2 inhibitors for cancer therapy.
Lyubomir T Vassilev.
Trends Mol Med, 2006 Nov 28; 13(1). PMID: 17126603
Highly Cited. Review.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.
Sanjeev Shangary, Dongguang Qin, +19 authors, Shaomeng Wang.
Proc Natl Acad Sci U S A, 2008 Mar 05; 105(10). PMID: 18316739    Free PMC article.
Highly Cited.
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Katherine Stemke-Hale, Ana Maria Gonzalez-Angulo, +19 authors, Bryan T Hennessy.
Cancer Res, 2008 Aug 05; 68(15). PMID: 18676830    Free PMC article.
Highly Cited.
Targeting the MDM2-p53 interaction for cancer therapy.
Sanjeev Shangary, Shaomeng Wang.
Clin Cancer Res, 2008 Sep 04; 14(17). PMID: 18765522    Free PMC article.
Highly Cited. Review.
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.
Jason I Herschkowitz, Xiaping He, Cheng Fan, Charles M Perou.
Breast Cancer Res, 2008 Sep 11; 10(5). PMID: 18782450    Free PMC article.
Highly Cited.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
Robert J Crowder, Chanpheng Phommaly, +14 authors, Matthew J Ellis.
Cancer Res, 2009 Apr 16; 69(9). PMID: 19366795    Free PMC article.
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, +12 authors, Johann S de Bono.
N Engl J Med, 2009 Jun 26; 361(2). PMID: 19553641
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Nicholas Turner, Alex Pearson, +12 authors, Alan Ashworth.
Cancer Res, 2010 Feb 25; 70(5). PMID: 20179196    Free PMC article.
Highly Cited.
Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM.
Charles J Vaske, Stephen C Benz, +5 authors, Joshua M Stuart.
Bioinformatics, 2010 Jun 10; 26(12). PMID: 20529912    Free PMC article.
Highly Cited.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, +12 authors, James Carmichael.
Lancet, 2010 Jul 09; 376(9737). PMID: 20609467
Highly Cited.
Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation.
Joshua D Stender, Kyuri Kim, +6 authors, Benita S Katzenellenbogen.
Mol Cell Biol, 2010 Jun 16; 30(16). PMID: 20547749    Free PMC article.
Highly Cited.
Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53.
Chad Deisenroth, Aaron R Thorner, +2 authors, Yanping Zhang.
Mol Cell Biol, 2010 Jun 16; 30(16). PMID: 20547751    Free PMC article.
MDM2 is a central node in the p53 pathway: 12 years and counting.
Gareth L Bond, Wenwei Hu, Arnold J Levine.
Curr Cancer Drug Targets, 2005 Feb 22; 5(1). PMID: 15720184
Highly Cited. Review.
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Matthew J Ellis, Yu Tao, +11 authors, J Michael Dixon.
J Clin Oncol, 2006 Jun 07; 24(19). PMID: 16754938
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Todd W Miller, Justin M Balko, +16 authors, Carlos L Arteaga.
Cancer Discov, 2011 Nov 04; 1(4). PMID: 22049316    Free PMC article.
Highly Cited.
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
John P Leonard, Ann S LaCasce, +19 authors, Geoffrey I Shapiro.
Blood, 2012 Mar 03; 119(20). PMID: 22383795
Highly Cited.
Gene-specific patterns of coregulator requirements by estrogen receptor-α in breast cancer cells.
Kwang Won Jeong, Rajas Chodankar, +2 authors, Michael R Stallcup.
Mol Endocrinol, 2012 May 01; 26(6). PMID: 22543272    Free PMC article.
The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
Sohrab P Shah, Andrew Roth, +56 authors, Samuel Aparicio.
Nature, 2012 Apr 13; 486(7403). PMID: 22495314    Free PMC article.
Highly Cited.
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Matthew J Ellis, Li Ding, +56 authors, Elaine R Mardis.
Nature, 2012 Jun 23; 486(7403). PMID: 22722193    Free PMC article.
Highly Cited.
The landscape of cancer genes and mutational processes in breast cancer.
Philip J Stephens, Patrick S Tarpey, +60 authors, Michael R Stratton.
Nature, 2012 Jun 23; 486(7403). PMID: 22722201    Free PMC article.
Highly Cited.
Sequence analysis of mutations and translocations across breast cancer subtypes.
Shantanu Banerji, Kristian Cibulskis, +44 authors, Matthew Meyerson.
Nature, 2012 Jun 23; 486(7403). PMID: 22722202    Free PMC article.
Highly Cited.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, +29 authors, Samuel Aparicio.
Nature, 2012 Apr 24; 486(7403). PMID: 22522925    Free PMC article.
Highly Cited.
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.
Stephen K Chia, Vivien H Bramwell, +12 authors, Torsten O Nielsen.
Clin Cancer Res, 2012 Jun 20; 18(16). PMID: 22711706    Free PMC article.
Highly Cited.
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Denise A Yardley, Roohi R Ismail-Khan, +7 authors, Jane B Trepel.
J Clin Oncol, 2013 May 08; 31(17). PMID: 23650416    Free PMC article.
Highly Cited.
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
Integrated genomic analyses of ovarian carcinoma.
Cancer Genome Atlas Research Network.
Nature, 2011 Jul 02; 474(7353). PMID: 21720365    Free PMC article.
Highly Cited.
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Cesar G Sanchez, Cynthia X Ma, +5 authors, Matthew J Ellis.
Breast Cancer Res, 2011 Mar 03; 13(2). PMID: 21362200    Free PMC article.
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
José Baselga, Mario Campone, +18 authors, Gabriel N Hortobagyi.
N Engl J Med, 2011 Dec 14; 366(6). PMID: 22149876    Free PMC article.
Highly Cited.
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Patrick J Roberts, John E Bisi, +7 authors, Norman E Sharpless.
J Natl Cancer Inst, 2012 Feb 04; 104(6). PMID: 22302033    Free PMC article.
Highly Cited.
Epigenetics in breast cancer: what's new?
Yi Huang, Shweta Nayak, +2 authors, Steffi Oesterreich.
Breast Cancer Res, 2011 Nov 15; 13(6). PMID: 22078060    Free PMC article.
Review.
Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia.
D J P M Stumpel, P Schneider, +4 authors, R W Stam.
Leukemia, 2011 Oct 22; 26(4). PMID: 22015773
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
Maggie C U Cheang, K David Voduc, +15 authors, Torsten O Nielsen.
Clin Cancer Res, 2012 Feb 22; 18(8). PMID: 22351696    Free PMC article.
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
Lyubomir T Vassilev, Binh T Vu, +9 authors, Emily A Liu.
Science, 2004 Jan 06; 303(5659). PMID: 14704432
Highly Cited.
Mode of estrogen action on cell proliferative kinetics in CAMA-1 cells. I. Effect of serum and estrogen.
B S Leung, A H Potter.
Cancer Invest, 1987 Jan 01; 5(3). PMID: 3651865
Distinct roles for cyclin-dependent kinases in cell cycle control.
S van den Heuvel, E Harlow.
Science, 1993 Dec 24; 262(5142). PMID: 8266103
Highly Cited.
The retinoblastoma protein and cell cycle control.
R A Weinberg.
Cell, 1995 May 05; 81(3). PMID: 7736585
Highly Cited. Review.
Cancer cell cycles.
C J Sherr.
Science, 1996 Dec 06; 274(5293). PMID: 8939849
Highly Cited. Review.
CDK inhibitors: positive and negative regulators of G1-phase progression.
C J Sherr, J M Roberts.
Genes Dev, 1999 Jul 01; 13(12). PMID: 10385618
Highly Cited. Review.
Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1.
J W Harbour, R X Luo, +2 authors, D C Dean.
Cell, 1999 Sep 28; 98(6). PMID: 10499802
Highly Cited.
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
George W Small, Yue Y Shi, Linda S Higgins, Robert Z Orlowski.
Cancer Res, 2007 May 08; 67(9). PMID: 17483361
Translating next generation sequencing to practice: opportunities and necessary steps.
Sitharthan Kamalakaran, Vinay Varadan, +5 authors, Lyndsay N Harris.
Mol Oncol, 2013 Jun 19; 7(4). PMID: 23769412    Free PMC article.
Review.
Luminal breast cancer: from biology to treatment.
Michail Ignatiadis, Christos Sotiriou.
Nat Rev Clin Oncol, 2013 Jul 25; 10(9). PMID: 23881035
Review.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
A Goldhirsch, E P Winer, +5 authors, Panel members.
Ann Oncol, 2013 Aug 07; 24(9). PMID: 23917950    Free PMC article.
Highly Cited.
Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2.
Benjamin Cieply, Joshua Farris, +2 authors, Steven M Frisch.
Cancer Res, 2013 Aug 15; 73(20). PMID: 23943797    Free PMC article.
Highly Cited.
Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.
Foluso O Ademuyiwa, Matthew J Ellis, Cynthia X Ma.
J Oncol, 2013 Aug 29; 2013. PMID: 23983689    Free PMC article.
Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.
Ashley G Rivenbark, Siobhan M O'Connor, William B Coleman.
Am J Pathol, 2013 Sep 03; 183(4). PMID: 23993780    Free PMC article.
Review.
Is upregulation of BCL2 a determinant of tumor development driven by inactivation of CDH1/E-cadherin?
Inga Karch, Elisa Schipper, +3 authors, Matthias Christgen.
PLoS One, 2013 Sep 12; 8(8). PMID: 24023670    Free PMC article.
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Shunqiang Li, Dong Shen, +52 authors, Matthew J Ellis.
Cell Rep, 2013 Sep 24; 4(6). PMID: 24055055    Free PMC article.
Highly Cited.
Mutational analysis of breast cancer: guiding personalized treatments.
Matthew J Ellis.
Breast, 2013 Oct 01; 22 Suppl 2. PMID: 24074785    Free PMC article.
Review.
The molecular diversity of Luminal A breast tumors.
Giovanni Ciriello, Rileen Sinha, +5 authors, Nikolaus Schultz.
Breast Cancer Res Treat, 2013 Oct 08; 141(3). PMID: 24096568    Free PMC article.
Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.
Matthew J Ellis, Michael Gillette, +9 authors, Clinical Proteomic Tumor Analysis Consortium (CPTAC).
Cancer Discov, 2013 Oct 15; 3(10). PMID: 24124232    Free PMC article.
Wnt signaling in triple negative breast cancer is associated with metastasis.
Nandini Dey, Benjamin G Barwick, +11 authors, Brian R Leyland-Jones.
BMC Cancer, 2013 Nov 12; 13. PMID: 24209998    Free PMC article.
Highly Cited.
Association of microRNAs and pathologic response to preoperative chemotherapy in triple negative breast cancer: preliminary report.
Agnieszka Kolacinska, Jan Morawiec, +9 authors, Izabela Zawlik.
Mol Biol Rep, 2014 Jan 29; 41(5). PMID: 24469723    Free PMC article.
ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
Samira A Brooks, A Rose Brannon, +12 authors, W Kimryn Rathmell.
Eur Urol, 2014 Mar 13; 66(1). PMID: 24613583    Free PMC article.
Highly Cited.
Regulation of mammary epithelial cell homeostasis by lncRNAs.
Amy N Shore, Jeffrey M Rosen.
Int J Biochem Cell Biol, 2014 Apr 01; 54. PMID: 24680897    Free PMC article.
Review.
ARF and p53 coordinate tumor suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis.
Jason T Forys, Catherine E Kuzmicki, +3 authors, Jason D Weber.
Cell Rep, 2014 Apr 15; 7(2). PMID: 24726362    Free PMC article.
Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients.
Agnieszka Kolacinska, Jan Morawiec, +8 authors, Izabela Zawlik.
DNA Cell Biol, 2014 May 29; 33(9). PMID: 24865188    Free PMC article.
Pathway-driven discovery of rare mutational impact on cancer.
TaeJin Ahn, Taesung Park.
Biomed Res Int, 2014 Jun 03; 2014. PMID: 24883302    Free PMC article.
Mammary stem cells and the differentiation hierarchy: current status and perspectives.
Jane E Visvader, John Stingl.
Genes Dev, 2014 Jun 04; 28(11). PMID: 24888586    Free PMC article.
Highly Cited. Review.
Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer.
Meiyun Fan, Aarti Sethuraman, +2 authors, Lawrence M Pfeffer.
Breast Cancer Res Treat, 2014 Jul 09; 146(3). PMID: 25001613    Free PMC article.
Notch2 activation is protective against anticancer effects of zerumbone in human breast cancer cells.
Anuradha Sehrawat, Kozue Sakao, Shivendra V Singh.
Breast Cancer Res Treat, 2014 Jul 21; 146(3). PMID: 25038880    Free PMC article.
How many etiological subtypes of breast cancer: two, three, four, or more?
William F Anderson, Philip S Rosenberg, +2 authors, Mark E Sherman.
J Natl Cancer Inst, 2014 Aug 15; 106(8). PMID: 25118203    Free PMC article.
Highly Cited. Review.
Intrinsic cancer subtypes--next steps into personalized medicine.
Cristina Santos, Rebeca Sanz-Pamplona, +6 authors, Ramon Salazar.
Cell Oncol (Dordr), 2015 Jan 15; 38(1). PMID: 25586691
Review.
New concepts in breast cancer genomics and genetics.
Rodrigo Goncalves, Wayne A Warner, Jingqin Luo, Matthew J Ellis.
Breast Cancer Res, 2015 Jan 22; 16(5). PMID: 25606588    Free PMC article.
Review.
The origin of breast tumor heterogeneity.
A Skibinski, C Kuperwasser.
Oncogene, 2015 Feb 24; 34(42). PMID: 25703331    Free PMC article.
Highly Cited. Review.
Lobular breast cancer: molecular basis, mouse and cellular models.
Matthias Christgen, Patrick W B Derksen.
Breast Cancer Res, 2015 Mar 12; 17. PMID: 25757734    Free PMC article.
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.
Christopher D Hart, Ilenia Migliaccio, +3 authors, Angelo Di Leo.
Nat Rev Clin Oncol, 2015 May 27; 12(9). PMID: 26011489
Review.
Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits.
Bhupinder Pal, Yunshun Chen, +10 authors, Jane E Visvader.
Breast Cancer Res, 2015 Jun 18; 17. PMID: 26080807    Free PMC article.
Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival.
Se Kyung Lee, Soo Youn Bae, +6 authors, Seok Jin Nam.
PLoS One, 2015 Aug 05; 10(8). PMID: 26241661    Free PMC article.
Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
D Merino, S W Lok, J E Visvader, G J Lindeman.
Oncogene, 2015 Aug 11; 35(15). PMID: 26257067
Review.
Use of semantic workflows to enhance transparency and reproducibility in clinical omics.
Christina L Zheng, Varun Ratnakar, Yolanda Gil, Shannon K McWeeney.
Genome Med, 2015 Aug 21; 7. PMID: 26289940    Free PMC article.
PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.
Kinnari Pandya, Debra Wyatt, +14 authors, Clodia Osipo.
Clin Cancer Res, 2015 Sep 10; 22(1). PMID: 26350262    Free PMC article.
Translating cancer genomes and transcriptomes for precision oncology.
Sameek Roychowdhury, Arul M Chinnaiyan.
CA Cancer J Clin, 2015 Nov 04; 66(1). PMID: 26528881    Free PMC article.
Review.
The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective.
Julie Dutil, Volha A Golubeva, +3 authors, Alvaro N Monteiro.
Breast Cancer Res Treat, 2015 Nov 14; 154(3). PMID: 26564481    Free PMC article.
PI3K/Akt/mTOR inhibitors in breast cancer.
Joycelyn Jx Lee, Kiley Loh, Yoon-Sim Yap.
Cancer Biol Med, 2016 Jan 19; 12(4). PMID: 26779371    Free PMC article.
Highly Cited. Review.
Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
Muhammad Hasan Bashari, Fengjuan Fan, +11 authors, Klaus Podar.
Breast Cancer Res, 2016 Feb 28; 18(1). PMID: 26921175    Free PMC article.
Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling.
Matthew J Rioth, Ramya Thota, +2 authors, Jeremy L Warner.
J Am Med Inform Assoc, 2016 Mar 31; 23(4). PMID: 27026612    Free PMC article.
Estrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer.
Jaime Matta, Luisa Morales, +6 authors, Erick Suárez.
PLoS One, 2016 Apr 01; 11(3). PMID: 27032101    Free PMC article.
A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.
Lijun Cheng, Bryan P Schneider, Lang Li.
J Am Med Inform Assoc, 2016 Apr 24; 23(4). PMID: 27107440    Free PMC article.
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Masaru Katoh.
Int J Mol Med, 2016 Jun 02; 38(1). PMID: 27245147    Free PMC article.
Highly Cited. Review.
Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
Pradip De, Jennifer H Carlson, +3 authors, Nandini Dey.
Oncotarget, 2016 Jun 10; 7(28). PMID: 27281609    Free PMC article.
Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.
Casey Stottrup, Tiffany Tsang, Y Rebecca Chin.
Mol Cancer Ther, 2016 Jun 15; 15(8). PMID: 27297869    Free PMC article.
Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study.
André Hennigs, Fabian Riedel, +13 authors, Andreas Schneeweiss.
BMC Cancer, 2016 Sep 17; 16(1). PMID: 27634735    Free PMC article.
Recent developments and translational aspects in targeted therapy for metastatic breast cancer.
Maximilian Marhold, Rupert Bartsch, Christoph Zielinski.
ESMO Open, 2016 Nov 16; 1(3). PMID: 27843605    Free PMC article.
Review.
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls.
Peter Horak, Stefan Fröhling, Hanno Glimm.
ESMO Open, 2016 Dec 10; 1(5). PMID: 27933214    Free PMC article.
Review.
RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer.
Ohad Tarcic, Roy Z Granit, +8 authors, Moshe Oren.
Cell Death Differ, 2017 Feb 06; 24(4). PMID: 28157208    Free PMC article.
Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
Woonyoung Choi, Andrea Ochoa, +8 authors, Seth P Lerner.
Eur Urol, 2017 Apr 04; 72(3). PMID: 28365159    Free PMC article.
Highly Cited. Review.
Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.
Nandini Dey, Amy Krie, +7 authors, Brian Leyland-Jones.
Int J Mol Sci, 2017 Jun 08; 18(6). PMID: 28590426    Free PMC article.
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
Paz Polak, Jaegil Kim, +25 authors, Gad Getz.
Nat Genet, 2017 Aug 22; 49(10). PMID: 28825726    Free PMC article.
Highly Cited.
Intrinsic subtypes and bladder cancer metastasis.
David J McConkey, Woonyoung Choi, Andrea Ochoa, Colin P N Dinney.
Asian J Urol, 2016 Oct 01; 3(4). PMID: 29264194    Free PMC article.
Review.
Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.
Gerjon J Ikink, Mandy Boer, +6 authors, John Hilkens.
Oncogene, 2018 Jan 13; 37(12). PMID: 29326437    Free PMC article.
Is Mastectomy Oncologically Safer than Breast-Conserving Treatment in Early Breast Cancer?
Fabian Riedel, André Hennigs, +5 authors, Jörg Heil.
Breast Care (Basel), 2018 Feb 20; 12(6). PMID: 29456470    Free PMC article.
Review.
Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.
Andrew Baker, Debra Wyatt, +8 authors, Clodia Osipo.
Oncogene, 2018 May 11; 37(33). PMID: 29743588
Signature program: a platform of basket trials.
Eric D Slosberg, Barinder P Kang, +9 authors, August Salvado.
Oncotarget, 2018 May 17; 9(30). PMID: 29765547    Free PMC article.
Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies.
Evelyn M Brosnan, Carey K Anders.
Ann Transl Med, 2018 Jun 19; 6(9). PMID: 29911111    Free PMC article.
Review.
Therapeutic landscape in mutational triple negative breast cancer.
Yaqin Shi, Juan Jin, Wenfei Ji, Xiaoxiang Guan.
Mol Cancer, 2018 Jul 17; 17(1). PMID: 30007403    Free PMC article.
Review.
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.
Rania El Botty, Florence Coussy, +12 authors, Elisabetta Marangoni.
Oncotarget, 2018 Jul 25; 9(51). PMID: 30038706    Free PMC article.
Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression.
Harald Hessel, Manuela Poignée-Heger, +6 authors, Thomas Kirchner.
J Cancer, 2018 Aug 09; 9(15). PMID: 30087699    Free PMC article.
The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy.
Chenjing Zhu, Otilia Menyhart, Balázs Győrffy, Xia He.
BMC Cancer, 2019 Nov 07; 19(1). PMID: 31690268    Free PMC article.
PI3K Inhibitors in Breast Cancer Therapy.
Haley Ellis, Cynthia X Ma.
Curr Oncol Rep, 2019 Dec 13; 21(12). PMID: 31828441
Review.
miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC.
Xiaowei Shen, Jiaqi Lei, Lei Du.
Exp Ther Med, 2019 Dec 20; 19(1). PMID: 31853314    Free PMC article.
Latin American Study of Hereditary Breast and Ovarian Cancer LACAM: A Genomic Epidemiology Approach.
Javier Oliver, Rosalía Quezada Urban, +42 authors, Felipe Vaca Paniagua.
Front Oncol, 2020 Jan 11; 9. PMID: 31921681    Free PMC article.
Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay.
Pavalan Selvam, Meng-Chang Hsiao, +14 authors, Honey V Reddi.
Mol Diagn Ther, 2019 Nov 23; 24(1). PMID: 31754995
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Sarah Sammons, Noah S Kornblum, Kimberly L Blackwell.
Target Oncol, 2018 Aug 24; 14(1). PMID: 30136059    Free PMC article.
Review.
A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer.
S Speransky, P Serafini, +3 authors, N H Bishopric.
Breast Cancer Res Treat, 2019 Apr 22; 176(2). PMID: 31006104    Free PMC article.
A new view of the mammary epithelial hierarchy and its implications for breast cancer initiation and metastasis.
Lindsey J Anstine, Ruth Keri.
J Cancer Metastasis Treat, 2019 Jan 01; 5. PMID: 32395618    Free PMC article.
Gene Expression: the Key to Understanding HIV-1 Infection?
Melinda Judge, Erica Parker, Denise Naniche, Peter Le Souëf.
Microbiol Mol Biol Rev, 2020 May 15; 84(2). PMID: 32404327    Free PMC article.
Review.
Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations.
Zsuzsanna Suba.
J Oncol, 2020 Aug 11; 2020. PMID: 32774370    Free PMC article.
Review.
Cellular Plasticity of Mammary Epithelial Cells Underlies Heterogeneity of Breast Cancer.
Verónica Rodilla, Silvia Fre.
Biomedicines, 2018 Nov 06; 6(4). PMID: 30388868    Free PMC article.
Review.
CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer.
Alexander Ring, Cu Nguyen, +5 authors, Julie E Lang.
Cancers (Basel), 2018 Dec 24; 10(12). PMID: 30572639    Free PMC article.
ESR1 alterations and metastasis in estrogen receptor positive breast cancer.
Jonathan T Lei, Xuxu Gou, Sinem Seker, Matthew J Ellis.
J Cancer Metastasis Treat, 2019 May 21; 5. PMID: 31106278    Free PMC article.
Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer.
Susana Ros, Alan J Wright, +21 authors, Kevin M Brindle.
Cancer Cell, 2020 Sep 26; 38(4). PMID: 32976773    Free PMC article.
Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.
Aleix Prat, Barbara Adamo, +14 authors, Javier Cortés.
Sci Rep, 2014 Jan 05; 3. PMID: 24384914    Free PMC article.
Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.
Sarah Naomi Olsen, Ania Wronski, +13 authors, Karen Cichowski.
Cancer Discov, 2016 Dec 16; 7(2). PMID: 27974415    Free PMC article.
Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.
Toshifumi Wakai, Pankaj Prasoon, +3 authors, Masayuki Nagahashi.
Int J Clin Oncol, 2018 Dec 06; 24(2). PMID: 30515675
Review.
Clinical target sequencing for precision medicine of breast cancer.
Junko Tsuchida, Jami Rothman, +3 authors, Toshifumi Wakai.
Int J Clin Oncol, 2019 Jan 04; 24(2). PMID: 30604156
Review.
Network-guided prediction of aromatase inhibitor response in breast cancer.
Matthew Ruffalo, Roby Thomas, +3 authors, Ziv Bar-Joseph.
PLoS Comput Biol, 2019 Feb 12; 15(2). PMID: 30742607    Free PMC article.
Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
Yoon Ming Chin, Yoko Takahashi, +7 authors, Siew-Kee Low.
Cancer Sci, 2020 Oct 20; 112(1). PMID: 33075187    Free PMC article.
GREB1 regulates PI3K/Akt signaling to control hormone-sensitive breast cancer proliferation.
Corinne N Haines, Hope D Klingensmith, Makanko Komara, Craig J Burd.
Carcinogenesis, 2020 Sep 08; 41(12). PMID: 32894276    Free PMC article.
Targeted Neoadjuvant Therapies in HR+/HER2-Breast Cancers: Challenges for Improving pCR.
Nandini Dey, Jennifer Aske, Pradip De.
Cancers (Basel), 2021 Feb 04; 13(3). PMID: 33530335    Free PMC article.
Review.
Survival outcomes are associated with genomic instability in luminal breast cancers.
Lydia King, Andrew Flaus, Emma Holian, Aaron Golden.
PLoS One, 2021 Feb 04; 16(2). PMID: 33534788    Free PMC article.